# Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

> **NCT04373369** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** Vorolanib
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT04373369
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-07
- **Primary completion:** 2022-08-18
- **Final completion:** 2025-08-11
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Insufficient Funding/Staff
- **Last updated:** 2025-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04373369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04373369, "Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04373369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*